Mixed CAR-NK Cell Population for Solid Tumor Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches, such as CAR-NK cell therapy, are limited in their effectiveness against solid tumors, necessitating the development of enhanced methods to expand and maintain genetically modified cells that can specifically target and kill cancer cells.
Innovation Solution
A mixed population of genetically modified cells, including T cells and NK cells, expressing different antigen binding domains for expansion and targeting, are administered to patients, where the cells express distinct antigen binding domains for both expanding and killing tumor cells, enhancing their therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a single type of genetically modified cell is used for immunotherapy, then the treatment approach is simple, but the expansion and therapeutic efficacy are limited
Solution Approach 1:
The cell population is segmented into distinct functional subsets: expansion cells (expressing expansion antigen binding domains) and killing cells (expressing tumor-targeting antigen binding domains). This segmentation allows each subset to specialize in its function, with expansion cells rapidly proliferating and killing cells eliminating tumors, thereby achieving both high expansion and therapeutic efficacy without requiring a single complex cell type to perform all functions simultaneously.
Solution Approach 2:
The mixed cell population creates a universal therapeutic system where different cell types work together to achieve multiple objectives: rapid expansion, tumor targeting, and sustained anti-tumor activity. The system universally addresses both the need for sufficient cell numbers and the need for effective tumor killing, resolving the contradiction between simplicity and efficacy.
2Quantity of substance
If genetically modified cells are expanded rapidly, then therapeutic dosage is achieved, but control over cell behavior and specificity may be compromised
Solution Approach 1:
Different cell types within the mixed population possess local quality specializations: expansion cells are optimized for rapid proliferation with specific antigen binding domains targeting expansion antigens, while killing cells are optimized for tumor recognition and cytotoxicity with specific antigen binding domains targeting tumor antigens. This local quality differentiation ensures that each cell type maintains controlled, predictable behavior suited to its specific function, even as the overall population expands rapidly.
3Adaptability or versatility
If multiple antigen binding domains are expressed on the same cell, then dual functionality is achieved, but cell complexity and manufacturing difficulty increase
Solution Approach 1:
Instead of creating complex single cells with multiple antigen binding domains, the system segments functionality across separate cell types. Each cell type expresses a limited number of specific antigen binding domains appropriate to its function, simplifying the genetic modification and manufacturing process for each cell type while achieving dual functionality at the population level through the coordinated action of expansion cells and killing cells.
Data Source
AI summary
The present disclosure relates to compositions and methods for enhancing NK cell response and/or maintenance in vivo and/or in vitro. For example, a method of enhancing NK cell-based therapy comprises administering a mixed population of NK cells comprising modified NK cells comprising a first chimeric antigen receptor (CAR) and modified NK cells comprising a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.